A Phase 3 interventional study of Teduglutide and Syringe in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 19th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 17th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2018.
This study's enrollment of 7 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 17th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
Drug: Teduglutide · Device: Syringe · Device: Needle · Device: Vial Adapter for Device
Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
Vial adapter for device is approved for use in Japan by PMDA.
Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Change from baseline in weekly PS volume at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Percent change from baseline in weekly PS volume at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20
Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.
Time frame: Baseline, Week 20
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.
Time frame: Baseline, Week 24
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)
Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)
Change from baseline in days per week of PS at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)
Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)
Number of participants who were completely weaned off PS at Week 24/EOT was reported.
Time frame: Week 24/EOT
Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide
AUC0-t of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Maximum Plasma Concentration (Cmax) of Teduglutide
Cmax of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Time to Maximum Plasma Concentration (Tmax) of Teduglutide
Tmax of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Terminal-phase Half-life (T1/2) of Teduglutide
T1/2 of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Apparent Clearance (CL/F) of Teduglutide
CL/F of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Apparent Volume of Distribution (Vz/F) of Teduglutide
Vz/F of teduglutide was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.
Time frame: From start of study drug administration up to EOT/ET (up to Week 28)
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)
12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.
Time frame: From start of study drug administration up to EOT/ET (up to Week 28)
Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)
Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)
Change from baseline in pulse rate at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)
Change from baseline in body temperature at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)
Change from baseline in hemoglobin at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)
Change from baseline in hematocrit at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)
Change from baseline in serum blood urea nitrogen at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)
Change from baseline in creatinine at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)
Change from baseline in urine sodium at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)
Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.
Time frame: EOT/ET (up to Week 28)
Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)
Change from baseline in 48-hour urine output at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)
Change from baseline in body weight at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)
Change from baseline in BMI at EOT/ET was reported.
Time frame: Baseline, EOT/ET (up to Week 28)
Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)
GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.
Time frame: Week 24/ET
The study was conducted at 5 sites in Japan between 06 July 2018 (first participant first visit) and 06 August 2019 (last participant last visit).
| Milestone | Teduglutide |
|---|---|
| Started | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
Change from baseline in weekly PS volume at EOT/ET was reported.
| Liter per week (L/Week) | Teduglutide |
|---|---|
| Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET) | -2.92 ± 3.463 |
Percent change from baseline in weekly PS volume at EOT/ET was reported.
| Percent change | Teduglutide |
|---|---|
| Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET) | -22.19 ± 24.953 |
Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.
| Percentage of participants | Teduglutide |
|---|---|
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20 | 66.7 |
Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.
| Percentage of participants | Teduglutide |
|---|---|
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 | 66.7 |
Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.
| Percentage of participants | Teduglutide |
|---|---|
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET) | 57.1 |
Change from baseline in days per week of PS at EOT/ET was reported.
| Days per Week | Teduglutide |
|---|---|
| Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET) | -0.43 ± 1.134 |
Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.
| Micromoles (mcmol) | Teduglutide |
|---|---|
| Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET) | 11.973 ± 11.7309 |
Number of participants who were completely weaned off PS at Week 24/EOT was reported.
| Participants | Teduglutide |
|---|---|
| Weaned Off Parenteral Support: No | 7 |
| Weaned Off Parenteral Support: Yes | 0 |
AUC0-t of teduglutide was reported.
| Hour*nanogram per milliliter (h*ng/mL) | Teduglutide |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide | 240.3 ± 80.651 |
Cmax of teduglutide was reported.
| Nanograms per milliliter (ng/mL) | Teduglutide |
|---|---|
| Maximum Plasma Concentration (Cmax) of Teduglutide | 49.50 ± 16.427 |
Tmax of teduglutide was reported.
| Hour | Teduglutide |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Teduglutide | 3.00 (1.87 to 5.92) |
T1/2 of teduglutide was reported.
| Hour | Teduglutide |
|---|---|
| Terminal-phase Half-life (T1/2) of Teduglutide | 1.09 (0.751 to 1.30) |
CL/F of teduglutide was reported.
| Milliliter per hour (mL/h) | Teduglutide |
|---|---|
| Apparent Clearance (CL/F) of Teduglutide | 10858.9 ± 4038.5 |
Vz/F of teduglutide was reported.
| Milliliter (mL) | Teduglutide |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Teduglutide | 17167.4 ± 8371.9 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 7 |
12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | 0 |
Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.
| Millimetre of mercury (mmHg) | Teduglutide |
|---|---|
| Systolic Blood Pressure: EOT (up to Week 28) | 2.4 ± 19.37 |
| Diastolic Blood Pressure: EOT (up to Week 28) | 6.6 ± 20.59 |
Change from baseline in pulse rate at EOT/ET was reported.
| Beats per minute (beats/min) | Teduglutide |
|---|---|
| Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET) | 2.6 ± 9.88 |
Change from baseline in body temperature at EOT/ET was reported.
| Degree Celsius | Teduglutide |
|---|---|
| Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET) | -0.03 ± 0.411 |
Change from baseline in hemoglobin at EOT/ET was reported.
| Gram per liter (g/L) | Teduglutide |
|---|---|
| Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET) | -3.9 ± 12.94 |
Change from baseline in hematocrit at EOT/ET was reported.
| Volume per volume (v/v) | Teduglutide |
|---|---|
| Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET) | -0.014 ± 0.0355 |
Change from baseline in serum blood urea nitrogen at EOT/ET was reported.
| mmol/L | Teduglutide |
|---|---|
| Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET) | 0 ± 0 |
Change from baseline in creatinine at EOT/ET was reported.
| Micromoles per liter (mcmol/L) | Teduglutide |
|---|---|
| Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET) | -5.6 ± 8.42 |
Change from baseline in urine sodium at EOT/ET was reported.
| millimoles per liter (mmol/L) | Teduglutide |
|---|---|
| Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET) | -2.1 ± 64.92 |
Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.
| Participants | Teduglutide |
|---|---|
| Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET) | 1 |
Change from baseline in 48-hour urine output at EOT/ET was reported.
| Milliliter per day (mL/day) | Teduglutide |
|---|---|
| Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET) | 213.57 ± 242.757 |
Change from baseline in body weight at EOT/ET was reported.
| kilogram (kg) | Teduglutide |
|---|---|
| Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET) | 0.164 ± 1.1146 |
Change from baseline in BMI at EOT/ET was reported.
| Kilograms per square meter (kg/m^2) | Teduglutide |
|---|---|
| Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET) | 0.07 ± 0.441 |
GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.
| Participants | Teduglutide |
|---|---|
| Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination) | 0 |
Collected over From start of study drug administration up to EOT/ET (up to Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teduglutide | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | Teduglutide |
|---|---|
| Device related infectionInfections and infestations | 1/7 |
| Medical device site infectionInfections and infestations | 1/7 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/7 |
| EpilepsyNervous system disorders | 1/7 |
| Event | Teduglutide |
|---|---|
| Abdominal distensionGastrointestinal disorders | 2/7 |
| Injection site reactionGeneral disorders | 2/7 |
| PyrexiaGeneral disorders | 2/7 |
| NasopharyngitisInfections and infestations | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 1/7 |
| PolycythaemiaBlood and lymphatic system disorders | 1/7 |
| Back painMusculoskeletal and connective tissue disorders | 1/7 |
| PhlebitisVascular disorders | 1/7 |
| Abdominal painGastrointestinal disorders | 1/7 |
| Abdominal pain lowerGastrointestinal disorders | 1/7 |
Safety population included all participants in the intent-to-treat (ITT) population who received at least 1 dose of study treatment.
| Age, Continuous(years) | Teduglutide |
|---|---|
| Mean | 40.4 ± 8.92 |
| Sex: Female, Male(Participants) | Teduglutide |
|---|---|
| Female | 4 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).
Ran from Jul 2018 to primary completion in Aug 2019, 13 months.
Results were first posted in Aug 2020, 11 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide